BioSig Technologies Partners with Sherpa Technology Group

Santa Monica, CA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has hired Sherpa Technology Group as its Intellectual Property Advisor.

Sherpa Technology Group (STG), formerly known as 3LP Advisors, is a leading Silicon Valley IP advisory firm that assists clients at the intersection of business, technology, and intellectual property. Established in 2008 by a small group of IP strategy veterans, STG has been providing intellectual property and technology strategy support, including partnership analysis, IP portfolio development, licensing, and monetization strategy support to a number of high profile Silicon Valley firms.

“We are very pleased to guide BioSig through their IP strategy at this important time in the Company’s development, and we look forward to exploring the opportunities for wider applications of BioSig’s technology,” commented Kevin Rivette(1), Managing Partner of Sherpa Technology Group, former Vice President at IBM Corporation, and former Senior Advisor to The Boston Consulting Group.

“Over the past six months we engaged with BioSig’s Board and management, as well as independently interacted with some of the Company’s strategic partners. We are very optimistic about BioSig’s future as a technology company with cutting-edge signal processing hardware and software,” added Andrew Filler(2), Partner and General Counsel of Sherpa Technology Group.

“As BioSig advances toward commercialization, we needed a world-class partner to build a solid IP strategy that will allow us to apply our technology to the new field of bioelectronic medicine. The impact that Kevin and the rest of the STG team(3) had on the IP strategies for some of the most well-known tech companies in the world was unmatched. Their ability to marry IP strategy with the establishment of sustainable and profitable business models was an ideal fit with our thinking and needs. Forging a long-term strategic relationship with STG will cement our intellectual property portfolio as a leader in the field,” said Kenneth Londoner, Chairman & Chief Executive Officer of BioSig Technologies, Inc.

(1) Kevin Rivette is the former Chairman of the USPTO oversight committee. In 2008, Kevin was named to the IP Hall of Fame by IAM magazine. In 2009 he was named one of “The World’s Leading IP Strategists”.
(2) Andrew Filler was named as one of the top two corporate IP attorneys in Silicon Valley by the San Jose/Silicon Valley Business Journal in 2011.
(3) Other key members include: Ralph Eckardt, Managing Partner, was named as one of “The World’s Leading IP Strategists” by IAM magazine; Peter Detkin, Senior Advisor, was named as the second most influential “IP market maker” in the world by IAM.

About Sherpa Technology Group
Founded in 2008 as 3LP Advisors, Sherpa Technology Group is a strategy and M&A advisor on technology and intellectual property ("IP") matters. The firm's clients range from Fortune 500 companies, to emerging technology companies, to investors and investment banks.
Sherpa Technology Group has world-class experience in IP strategy, management consulting, investment banking, and engineering. Members of its leadership team formerly ran The Boston Consulting Group's IP Strategy Practice and were responsible for authoring prominent books on IP strategy, including Rembrandts in the Attic (2000) and The Invisible Edge (2009). Sherpa Technology Group's team comprises IP pioneers who managed and monetized leading patent estates for the world's most recognizable companies, such as IBM Corporation, Intel Corporation, and Intellectual Ventures. The firm has offices in Silicon Valley and Boston.

About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary technology platform designed to improve the $4.6 billion electrophysiology (EP) marketplace ( Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System.  The technology has been developed to address an unmet need in a large and growing market.

The PURE EP System is a novel cardiac signal acquisition and display system, which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP System.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

Natasha Russkina
BioSig Technologies, Inc.
VP Business Development & Corporate Finance
+41 (0) 76 823 7527

Source: BioSig Technologies, Inc.